Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04315064 · ClinicalTrials.gov registry record · Early Phase 1
Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma
A Early Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT04315064 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 2 participants.
The verdict
NCT04315064, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety of infusions of panobinostat (MTX110) into the fourth ventricle of the brain or tumor resection cavity in patients with recurrent medulloblastoma and to assess the antitumor activity of simultaneous infusions of panobinostat (MTX110) into the fourth ventricle of the brain or resection cavity in patients with recurrent medulloblastoma based upon MRI scans and lumbar cerebrospinal fluid (CSF) cytology.
Interventions
- DRUG Treatment with MTX110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-21 |
| Est. Completion | 2023-05-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04315064
The ClinicalTrials.gov registry entry for NCT04315064 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with MTX110 is the first listed.
NCT04315064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04315064 about?
NCT04315064 is a clinical study titled "Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma". The purpose of this study is to establish the safety of infusions of panobinostat (MTX110) into the fourth ventricle of the brain or tumor resection cavity in patients with recurrent medulloblastoma and to assess the antitumor activity of simultaneous infusions of panobinostat (MTX110) into the four...
What is the current status of trial NCT04315064?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2020-04-21. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT04315064?
The interventions under investigation include: Treatment with MTX110 (DRUG).
Who is sponsoring clinical trial NCT04315064?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.